Here are the DEF 14A proxy statements from Crescent Biopharma, Inc. (CBIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBIO filings page.
Crescent Biopharma, Inc. is asking shareholders to vote at its virtual 2026 Annual General Meeting on June 2, 2026. The agenda includes electing two Class II directors (Susan Moran and Preferred Director Jonathan Violin), ratifying PricewaterhouseCoopers LLP as auditor for 2026, an advisory “say‑on‑pay” vote on executive compensation, and an advisory vote on how often future say‑on‑pay votes should occur.
Holders of ordinary shares and Series A non‑voting convertible preferred shares vote together for Dr. Moran, while only Series A holders vote for Dr. Violin and cannot vote on other proposals. Each Series A preferred share carries 1,000 votes on an as‑converted basis. The board recommends voting FOR both director nominees, FOR auditor ratification and executive compensation, and for a ONE‑YEAR frequency on future say‑on‑pay votes.